Fecal incontinence (FI), defined as the involuntary loss of rectal contents (eg, liquid or solid stool or gas),[@R1] is caused by disruptions in the interplay of components that help maintain fecal control. Loss of voluntary control of defecation imposes a considerable social and economic burden: patients report a severely impaired quality of life, and economic costs have been estimated at an average of \$4110 per patient annually (2010 US dollars).[@R2]

Community-based US prevalence data suggest that FI affects an estimated 8.3% of the population, or approximately 20 million adults.[@R3],[@R4] According to a US National Health and Nutrition Examination Survey, FI affects ∼8.4% of noninstitutionalized adults.[@R5] It is likely that FI is underestimated in the clinic because of several barriers, including misconceptions that FI is a natural part of aging, patient embarrassment, and social stigma.[@R6] FI prevalence increases with age and regardless of ethnicity, from 2.6% in people aged 20 to 29 years to 15.3% in people aged 70 years or older.[@R3] FI has been identified in at least 30% of residents in nursing homes[@R7],[@R8] and is a common reason for nursing home admissions in the elderly.[@R9] Elderly individuals with bowel problems impose a large burden on health care resources,[@R10] a burden that will likely increase as the population ages.[@R11]

Several risk factors for FI have been identified, and include obstetric trauma,[@R12] anal trauma or surgery,[@R13]--[@R15] pelvic radiotherapy for cancer,[@R15]--[@R18] smoking,[@R19] obesity,[@R19] diabetes,[@R15] and certain neurological conditions.[@R20] There is a greater prevalence among females than males, which is attributed to maternal injuries sustained during childbirth; however, other factors may play a role in late-onset FI, such as menopause, changes in the pelvic floor due to aging, and pudendal neuropathy.[@R3],[@R21]--[@R24]

FI is clinically subcategorized into 3 different types: (1) passive incontinence \[loss of stool without the urge to defecate, mainly attributable to internal anal sphincter (IAS) dysfunction and peripheral neuropathy\]; (2) urge incontinence \[inability to postpone defecation urge, related mainly to external anal sphincter (EAS) dysfunction\]; and (3) fecal seepage (involuntary loss of small amounts of stool), incomplete evacuation, and impaired rectal sensation).[@R6],[@R25]

Clinical evaluation begins with a full medical history to determine the cause and severity of the FI and its impact on patients' quality of life. Various scoring scales have been developed, including Wexner's Cleveland Clinic Florida Fecal Incontinence Score,[@R26] Vaizey's (St Mark's Incontinence Score),[@R27] the Fecal Incontinence Severity Index (FISI),[@R28] and the Rockwood Fecal Incontinence Quality of Life (FIQOL) Scale.[@R29] Several methods are available to evaluate the underlying cause of FI, including anorectal manometry to assess sensation and compliance, and anal endosonography or magnetic resonance imaging to assess the thickness and integrity of the puborectalis and the IAS and EAS.[@R6],[@R30]

Evidence suggests that the puborectalis may play an important role in anal continence.[@R31] Although not routinely performed in clinical practice, anal electromyography and pudendal nerve terminal motor latency testing may uncover neurological damage.[@R30] Recently, translumbar and transsacral motor-evoked potentials have provided evidence of neuropathy in patients with spinal cord injury and FI.[@R32],[@R33] Although these tests may help elucidate contributing factors to FI, many patients have multiple abnormalities contributing to symptoms[@R30]; therefore, FI should be recognized as a multifactorial disorder. This narrative review will focus on current and emerging treatment options for the management of FI.

METHODS
=======

A MEDLINE search was conducted for articles related to FI treatment published from January 1, 1990 through June 1, 2013, and included the search terms "fecal incontinence" and "management"; "artificial bowel sphincter"; "biofeedback"; "bulking agent"; "conservative"; "dynamic gracilis'; "pelvic floor repair"; "levatorplasty"; "overlapping AND end-to-end"; "sacral nerve stimulation"; "SECCA"; and "radiofrequency." The search was limited to articles published in English. Where relevant, the search was extended to unpublished trials on ClinicalTrials.gov. Bibliographies from included articles were manually reviewed for additional relevant publications.

RESULTS
=======

Management options for FI consist of conservative approaches, surgery (minimally invasive or invasive procedures), and injectable bulking agents.

Conservative Approaches
-----------------------

Conservative approaches are usually first-line therapy, particularly in patients with mild symptoms, and include dietary modifications, medication, muscle-strengthening exercises (Kegel exercises), biofeedback, and nonsurgical electrical nerve stimulation.[@R6] Dietary modification, such as avoiding caffeine, citrus fruits, spicy foods, alcohol, and dairy products (in patients with lactose intolerance) may help, but definitive evidence[@R22] for these restrictions is lacking. Opinions differ as to whether the addition of dietary fiber is beneficial or detrimental for the treatment of FI[@R6],[@R34],[@R35]; however, methylcellulose is resistant to fermentation by colonic microflora and may be less likely than some other forms of fiber to exacerbate diarrhea.[@R36]

Several medications are also available to treat FI. Antidiarrheal or antimotility agents, including loperamide or diphenoxylate, may be beneficial in patients with loose stools and urgency.[@R34] Limited evidence suggests that drugs administered to enhance sphincter tone, such as phenylepinephrine and sodium valproate, may be helpful in patients with passive FI and normal anal sphincter function.[@R34] In 1 clinical trial, the tricyclic antidepressant amitriptyline improved FI scores (scale, 1 to 18) from a median of 16 at baseline to 3 (*P*\<0.001) after 4 weeks of treatment.[@R37] In an open-label uncontrolled study, clonidine, an alpha~2~ adrenergic agonist, improved FI after 4 weeks of therapy[@R19]; however, a randomized, placebo-controlled study showed that clonidine did not significantly improve the number of episodes of FI or quality of life.[@R38]

Anal sphincter exercises (pelvic floor muscle training) and biofeedback therapy have been used alone and in combination for the treatment of FI. Anal sphincter exercises are performed to strengthen the puborectalis muscle, which is continuous with the EAS.[@R39] A single-center, randomized controlled study indicated that a regimen of pelvic floor exercises with biofeedback was nearly twice as effective as pelvic floor exercises alone, with 44% versus 21% of patients achieving complete continence at 3 months, respectively (*P*=0.008).[@R39] In addition, symptom relief was reported for 76% of patients using biofeedback and pelvic floor exercises compared with 41% of patients performing pelvic floor exercises alone (*P*\<0.01), and patients adjunctively using biofeedback had greater reductions in FISI scores (Fig. [1](#F1){ref-type="fig"}).[@R40] In a more recent randomized study comparing 2 different pelvic floor exercise regimens, both with biofeedback, 59 of the 69 patients (86%) had improved continence with 20% fully continent, with no statistically significant differences between exercise regimens.[@R41] A 2012 systematic review of randomized or quasirandomized controlled trials of patients performing anal sphincter exercises and/or receiving biofeedback and/or surface electrical stimulation of the anal sphincter concluded that the addition of biofeedback or electrical stimulation was superior to exercise alone in patients who had previously failed to respond to other conservative treatments.[@R39]

![Fecal Incontinence Severity Index (FISI) scores at baseline, pretreatment (end of run-in), and at 3 months posttreatment in patients treated with biofeedback versus pelvic floor exercise (PFE). At the 3-month follow-up, patients in the biofeedback group had greater reductions in FISI scores versus patients in the PFE group (*P*=0.01, ANOVA). \**P*=0.01, biofeedback versus PFE. Adapted from Heymen et al.[@R40]](mcg-48-752-g001){#F1}

As indicated above, nonsurgical (surface) electrical stimulation, alone or in combination with biofeedback, has also proven useful. One study found the combination of electrical stimulation 20 minutes twice daily, and biofeedback was superior to electrical stimulation alone: 53.8% of 39 patients receiving the combination were continent at the end of treatment versus none of 41 patients in the electrical stimulation-alone group.[@R42] In a small study of transcutaneous sacral nerve stimulation (SNS) applied 2 hours daily, 11 of 17 patients (69%) had improved symptoms, measured by FISI at 3 months, with improvements from a baseline of approximately 28 to 40 points as rated by both patients and the surgeon. Although the continence score improved by \>50% in only 5 patients (31%) at 3 months, 2 were fully continent. Improvement continued during a mean follow-up of 19.7 months, with 53% of patients showing improvement of \>50% in FISI scores.[@R43]

Transcutaneous and percutaneous posterior tibial nerve stimulation have been tried in patients with FI. In a large well-designed, multicenter, randomized, sham-controlled trial, transcutaneous posterior tibial nerve stimulation was no more efficacious than sham treatment.[@R44] Small studies evaluating implants of percutaneous needles in the posterior tibial nerve have reported modest results.[@R45]--[@R49] This includes results from a small, sham-controlled trial (11 treated patients vs. 8 sham-treated patients),[@R50] but results from large, randomized controlled trials are lacking.

Surgery
-------

Surgical options for FI may be considered in patients who fail conservative approaches. Several types of surgical management strategies are available for the treatment of FI, including direct surgical repair of defects, deformities, or obstruction; sphincter modulation; or fecal diversion. These various strategies include both invasive and less (minimally) invasive procedures.

### Minimally Invasive Procedures

The SECCA procedure (or radiofrequency anal sphincter remodeling) involves delivering temperature-controlled radiofrequency energy to the anorectal junction.[@R51] Although technically a nonsurgical procedure, the mechanism of action---tissue damage and wound healing---is considered invasive. This procedure results in tissue damage, remodeling, scarring, and contraction to potentially narrow the anal canal.[@R52],[@R53] Data on the SECCA procedure are variable, and results from randomized controlled trials are lacking. The technique's pioneers reported 5-year follow-up of 19 patients, noting that 12-month improvements versus baseline in mean FI scores and FIQOL scores were sustained at 5 years.[@R54] Other studies have also reported improvements in one or both these measures, albeit over a shorter time duration,[@R51],[@R55],[@R56] and many patients continued to have moderate FI.[@R51],[@R56]

SNS is an established, FDA-approved technique for neuromodulation in patients with FI. A low-amplitude electrical current is applied to a sacral nerve, usually S3, via an electrode in the sacral foramen. An advantage of SNS over alternative surgical techniques is the ability to evaluate patient response to SNS, via a temporary external neurostimulator, before permanent neurostimulator implantation.[@R57] SNS must be performed in the operating room and requires general or local anesthesia.

Reported efficacy of SNS has been inconsistent (Table [1](#T1){ref-type="table"}).[@R57]--[@R65] A literature review (n=14) on the clinical outcome of SNS and 9 other reports in patients with a sphincter lesion concluded that SNS has evolved to become a clinically efficient option in the treatment of FI. However, the need for long-term data has been noted with evidence of decreasing efficacy over time in more than a quarter of patients.[@R66] A meta-analysis examined 34 studies published between 2000 and 2008 and included 790 patients, of whom 665 received a permanent implant. The analysis indicated that, compared with maximal conservative therapy, SNS significantly improved functional and quality-of-life outcomes. Improvement in weekly FI episodes and FI scores was significantly greater in patients with intact versus impaired sphincters, but those with impaired sphincters experienced a greater increase in the ability to defer defecation. However, the complication rate among the 665 patients who had permanent SNS electrode implantation was ∼15%, resulting in permanent removal of the device in 18 (2.7%) patients.[@R67] A multicenter, prospective nonrandomized trial, not included as part of the previous meta-analysis, reported that 83% of 106 patients had ≥50% improvement in FI at 12 months and 40% became fully continent.[@R62] Improvements were sustained for 3 years.[@R61],[@R62] A total of 307 adverse events (AEs, 26 serious) in 96 patients were considered device or therapy related. Authors reported that this AE rate compared favorably with those associated with artificial bowel sphincter (ABS) and dynamic graciloplasty (reviewed below).[@R62] In 1 recent study reporting long-term benefits of SNS, 12 of 25 (48%) patients remained fully continent at the last follow-up visit (median, 114 mo; range, 96 to 164 mo). However, complications necessitated device removal in 3 (12%) patients.[@R59]

###### 

Efficacy and Safety of SNS in Patients With Chronic FI

![](mcg-48-752-g002)

Although SNS is expensive compared with more conservative approaches, some studies have shown SNS to be cost-effective compared with colostomy or dynamic graciloplasty.[@R68] However, it has been suggested that the costs may be significantly higher than previously thought, given that only 1 in 4 patients achieve complete continence, and that there is no reliable way to predict which patient will respond after permanent device implantation.[@R57] In addition, well-controlled randomized studies comparing SNS with sham treatment, particularly long-term studies, are lacking. Other forms of neurostimulation are being investigated, including pudendal nerve stimulation.[@R69]

Autologous myoblast injection is an investigational procedure in which myoblasts cultured from a striated muscle biopsy, taken surgically from a patient's pectoralis muscle, are injected into the EAS.[@R70] Daily anal electrical stimulation is required, both preprocedure (eg, 10 wk) and postprocedure (eg, 4 wk), to encourage myoblast integration into the tissue.[@R70] A pilot study (n=10) showed that at 12 months, Wexner FI scores had decreased by a mean of 14 U (*P*\<0.001) and Rockwood FIQOL scores had improved by a median of 30 U from baseline (*P*=0.005).[@R70]

### Invasive Procedures

Invasive surgical procedures are typically reserved for patients for whom conservative or less invasive options have failed. A 2013 systematic review of randomized trials of surgery for FI (through March 2013 and excluding prolapse repair) concluded that there was little evidence for or against surgery for FI.[@R53] However, the authors acknowledged that most of the studies evaluated were outdated and did not include more commonly used techniques.[@R53] If medical and other surgical therapies are ineffective in treating FI or are contraindicated, a colostomy may be considered.

Colostomy is an established surgical option typically reserved for patients with FI refractory to a variety of other treatment options.[@R6],[@R71] Although patients are generally apprehensive about receiving a colostomy,[@R71] survey data have noted improvement in quality of life following a colostomy compared with the FI experience before surgery,[@R72] as well as increased scores on coping, embarrassment, and lifestyle scales of the FIQOL instrument in patients who had received a colostomy compared with patients with FI.[@R73] Colostomy has been associated with bleeding, cardiac or respiratory events related to anesthesia, and parastomal hernia, but it remains a treatment option for patients with FI who have failed other therapies or for whom other therapies are not viable options.[@R71]

Anal sphincteroplasty involves repairing the damaged or weakened anal sphincter (using an overlapping or end-to-end technique) or creating a new functional sphincter using skeletal muscle from an adjacent site. In patients with FI of multiple etiologies, sphincter repair may be combined with pelvic floor repair.[@R53],[@R74] Long-term (\>5 y) functional outcomes have generally been disappointing, regardless of the technique used (Fig. [2](#F2){ref-type="fig"}).[@R75]--[@R85] Therefore, surgeons have turned to other surgical approaches, such as graciloplasty and artificial sphincters.

![Percentage of patients with "good" long-term outcomes after anal sphincter repair for FI. "Good" outcome was determined using definitions provided by the authors of each article. Adapted from Glasgow and Lowry.[@R75] Data from Malouf et al,[@R76] Halverson and Hull,[@R85] Zutshi et al,[@R77] Vaizey et al,[@R78] Bravo Gutierrez et al,[@R79] Zorcolo et al,[@R80] Barisic et al,[@R81] Maslekar et al,[@R82] Mevik et al,[@R83] and Johnson et al.[@R84]](mcg-48-752-g003){#F2}

Graciloplasty uses the patient's gracilis muscle to form a new sphincter around the anus. An electrical stimulator device may also be implanted in the abdominal wall (ie, dynamic graciloplasty) to sustain tone and help maintain continence.[@R86] In a multicenter international trial of dynamic graciloplasty, success, defined as a ≥50% reduction in incontinent episodes, was reported in 47 of 76 (62%), 37 of 67 (55%), and 35 of 62 (56%) patients at 12 months, 18 months, and 2 years posttreatment, respectively.[@R87] A systematic review reported dynamic graciloplasty success rates of 42% to 85%, with the most common AEs being infection (28%), stimulator malfunction (15%), and leg pain (13%).[@R88]

ABS devices comprise an inflatable cuff that acts as a new sphincter, a control pump, and a balloon that regulates the pressure and also acts as a fluid reservoir (Fig. [3](#F3){ref-type="fig"}).[@R89] The device maintains continence when the cuff is inflated and the patient releases the pressure when they wish to defecate.[@R90] Some health care providers have reportedly switched to using ABS devices rather than graciloplasty.[@R91]

![Artificial bowel sphincter (left) and the magnetic anal sphincter (right) devices. Reprinted with permission from Wong et al.[@R89] Copyright Wolters Kluwer Health.](mcg-48-752-g004){#F3}

Reports on the efficacy and safety of ABS devices have varied (Table [2](#T2){ref-type="table"}), and efficacy comparisons are confounded by the different scales used to assess improvement.[@R91]--[@R105] The largest single-center study published (n=52 patients and 85 devices; mean follow-up, \>5 y) showed that full continence is seldom achieved and that often a constant balance must be maintained between stool consistency and cuff pressures.[@R105] In a series of 17 patients, all experienced complications, 65% needed further surgery, and 65% had the device removed.[@R102] At 12 months, 33% and 67% of those retaining the device were completely continent to liquid and solid stools, respectively.[@R102] In a study of 21 patients who received an ABS device at 2 French academic centers, all patients developed ≥1 complication, and 18 patients (86%) required corrective surgery. The device was permanently removed from 17 patients (81%).[@R91]

###### 

Efficacy and Safety of Artificial Bowel Sphincter Device for FI
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Magnetic anal sphincter (MAS) devices comprise a series of interlinked titanium beads with internal magnetic cores that form a flexible ring that is placed to encircle the EAS (Fig. [3](#F3){ref-type="fig"}). During the pushing process of defecation,[@R89] the beads separate, allowing stool to pass[@R106] through the EAS. Subsequent to completion of a feasibility study,[@R106] a prospective, nonrandomized matched study (n=20) compared MAS and ABS devices.[@R89] No significant differences in early postoperative complications were observed, but the MAS group had a shorter time in surgery (62 vs. 97 min; *P*=0.0273) and a shorter hospital stay (4.5 vs. 10 d; *P*\<0.0001) compared with the ABS group.[@R89] Both groups achieved significant improvements from baseline in Wexner FI scores \[11-point decrease in each group; *P*=0.0002 (MAS), *P*=0.0001 (ABS)\] and FIQOL scores \[from 1.91 to 3.38 in the MAS group (*P*=0.0052) and from 1.80 to 3.55 in the ABS group (*P*=0.0089)\].[@R89] Four patients in the ABS group needed revisions; the device was removed in 2 patients because of pain and infection, respectively. At a mean follow-up of 8 months in the MAS group and 22.5 months in the ABS group, patients with either device still in situ had maintained initial postoperative improvements in FI scores, and similar significant improvements in FIQOL scores were observed in both the groups.[@R89]

Injectable Bulking Agents
-------------------------

Bulking agents vary in particle size and their capacity to migrate into the lymphatic system. Biocompatible bulking agents have been used successfully for many years for the treatment of urinary incontinence, and their potential use in FI is a logical progression.[@R107] For FI, the mechanism of action of bulking agents is to augment the walls of the IAS to close the anal canal or raise the pressure inside the anal canal, thus preventing incontinence.[@R1] Several bulking materials have been considered over the years. These include autologous fat, Teflon (rarely used because of safety issues), bovine glutaraldehyde cross-linked collagen, carbon-coated zirconium beads, polydimethylsiloxane elastomer (silicone), dextranomer microspheres in non-animal stabilized hyaluronic acid (NASHA Dx), hydrogel cross-linked with polyacrylamide, porcine dermal collagen, synthetic calcium hydroxyapatite ceramic microspheres, and polyacrylonitrile in cylinder form.[@R1]

NASHA Dx has been evaluated in several trials (Table [3](#T3){ref-type="table"}),[@R108]--[@R119] including a randomized, double-blind sham-controlled study in adults who had failed conservative therapies. Patients received NASHA Dx (n=136) or sham treatment (n=70) in an outpatient setting without anesthesia; patients with no persistent AEs but persistent FI after 1 month were offered 1 retreatment procedure.[@R109] Seventy-one (52%) patients in the active treatment group versus 22 (31%) in the sham group had a treatment response (≥50% improvement from baseline in the number of FI episodes) at 6 months (odds ratio, 2.36; *P*=0.0089).[@R109] There was a significant difference in the mean increase from baseline in number of incontinence-free days in the NASHA Dx group compared with sham group at month 6 (Fig. [4](#F4){ref-type="fig"}A)[@R109] and a significant improvement in FIQOL, coping, and behavior scores but not lifestyle, depression and self-perception, or embarrassment at month 6 (Fig. [4](#F4){ref-type="fig"}B).[@R109] Efficacy was not assessed in the sham group after 6 months; however, at 12 months, 69% of patients in the NASHA Dx group were responders.[@R109] Efficacy and long-term durability have been reported in open-label studies[@R110]--[@R114] and a comparative study versus biofeedback training (∼20 min daily, 5 d a week, for 6 mo; Table [3](#T3){ref-type="table"}).[@R108]

###### 

Clinical Trials of Bulking Agents
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![Response in patients treated with NASHA Dx (n=136) compared with sham treatment (n=70). A, The mean change from baseline in number of incontinence-free days over 2 weeks. B, The mean relative percentage change in FIQOL scores by category. FIQOL indicates Fecal Incontinence Quality of Life; NASHA Dx, dextranomer microspheres in non-animal stabilized hyaluronic acid. Adapted from Graf et al.[@R109]](mcg-48-752-g007){#F4}

The authors of a 2013 Cochrane review of 5 randomized studies of bulking agents concluded that, with the exception of the randomized NASHA Dx trial,[@R109] although several studies of bulking agents (eg, silicone) showed short-term benefits, the quality of most trials was poor (Table [3](#T3){ref-type="table"}).[@R1]

CONCLUSIONS
===========

FI is a common and distressing problem with a significant negative impact on patients' QOL, and conservative measures, such as lifestyle modifications and antidiarrheal agents, are considered first-line therapy for the management of FI and are generally effective in \<25% of patients. Biofeedback therapy, in combination with pelvic floor exercises, may provide short-term symptom relief in ∼75% of patients, but biofeedback therapy is not widely available and lacks standardization. Although the minimally invasive surgical procedure SNS may be useful (eg, ≥50% reduction from baseline in weekly FI episodes in 54% to 86% of patients), it has been associated with complications and a failure rate of approximately 15%. Invasive surgical procedures, such as anal sphincteroplasty, are effective initially, but they may not provide long-term benefit. Success rates with surgical sphincter replacement methods, such as graciloplasty and ABS, may be limited by complication rates, including device explantation. MAS is promising and may be superior to ABS, but controlled, adequately powered studies with long-term follow-up are needed. Injectable bulking agents, such as NASHA Dx, may provide an alternative in patients for whom conservative therapies are ineffective.
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